Article Text

Download PDFPDF
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure
  1. S Kasama1,
  2. T Toyama1,
  3. T Hatori1,
  4. H Sumino1,
  5. H Kumakura2,
  6. Y Takayama2,
  7. S Ichikawa2,
  8. T Suzuki1,
  9. M Kurabayashi1
  1. 1Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan
  2. 2Department of Internal Medicine, Cardiovascular Hospital of Central Japan, Gunma, Japan
  1. Correspondence to:
    Dr Shu Kasama
    Department of Cardiovascular Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-0034, Japan; s-kasama{at}


Objective: To evaluate the effects of valsartan on cardiac sympathetic nerve activity, plasma brain natriuretic peptide (BNP) concentration, cardiac function, and symptoms in patients with congestive heart failure (CHF) by comparison with those of enalapril.

Methods: 50 patients with CHF (left ventricular ejection fraction (LVEF) < 40%) were randomly assigned to valsartan (80 mg/day; n  =  25) or enalapril (5 mg/day; n  =  25). All patients were also treated with a loop diuretic. The delayed heart to mediastinum count (H/M) ratio, delayed total defect score (TDS), and washout rate were determined from 123I-meta-iodobenzylguanidine (MIBG) images. Plasma BNP concentrations were measured before and after six months of treatment. The left ventricular end diastolic volume (LVEDV) and LVEF were also determined by echocardiography.

Results: In patients receiving valsartan, TDS decreased from a mean (SD) of 43 (8) to 39 (10) (p < 0.01), H/M ratio increased from 1.70 (0.17) to 1.78 (0.22) (p < 0.05), washout rate decreased from 46 (11)% to 41 (10)% (p < 0.05), and plasma BNP concentration decreased from 237 (180) pg/ml to 143 (93) pg/ml (p < 0.05). In addition, LVEDV decreased from 172 (42) ml to 151 (45) ml (p < 0.05) and LVEF increased from 31 (7)% to 39 (10)% (p < 0.001). However, these parameters did not change significantly in patients receiving enalapril.

Conclusion: Plasma BNP concentration and 123I-MIBG scintigraphic and echocardiographic parameters improved significantly after six months of treatment with valsartan. These findings indicate that valsartan can improve cardiac sympathetic nerve activity and left ventricular performance in patients with CHF.

  • ACE, angiotensin converting enzyme
  • ARB, angiotensin receptor blocker
  • BNP, brain natriuretic peptide
  • CHF, congestive heart failure
  • H/M, heart to mediastinum count
  • 123I-MIBG, iodine-123 labelled meta-iodobenzylguanidine
  • LVEDV, left ventricular end diastolic volume
  • LVEF, left ventricular ejection fraction
  • NYHA, New York Heart Association
  • RAAS, renin-angiotensin-aldosterone system
  • SPECT, single photon emission computed tomographic
  • TDS, total defect score
  • Val-HeFT, valsartan heart failure trial
  • WR, washout rate
  • 123I-meta-iodobenzylguanidine
  • heart failure
  • angiotensin receptor blocker

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 13 September 2005

  • The authors have indicated they have no financial conflicts of interest.